Logo Chemed Corp.

Chemed Corp. (CHE) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Chemed Corp. · Health Care · ref. ETF XLV · 51 calls · price $520.27
🔔Price alertsCreate an alert →
What the company does: Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States.

📈 Chemed Corp. (CHE) stock price

$520.27+15.1% over range
Aug 28, 25low $368.59 · high $552.72Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 3 analysts
📊 JPI status : Chemed Corp. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 CHE price target & analyst consensusprice $520

The price target · all analysts combined (3 targets)
Highest target · 1 firm of 3$590+13.4%
Median target · of 3 targets$548+5.3%
Lowest target · 1 firm of 3$510-2.0%
Current price$520.27
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: B of A Securities74% of its targets hit on this sector (105 calls tested). It aims for $510 (-2.0 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 3 reliable analysts $548+5.3 %
How to read it: the 3 reliable firms are not filtered by optimism — 2 aim above the price, 1 below, hence their $548 median.
The consensus · 3 ratings (last 6 months)
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Chemed Corp.? The JPI assistant answers using our backtest data.

💰 Chemed Corp. dividend: yield, history & growth › open the full page

0.50%annual yield
📈 Steady dividend17 yrs of consecutive dividend increases
That's ~$2.40 per share per year.

📈 Chemed Corp. fundamentals: valuation, margins & growth › open the full page

P/E 27.6Net margin 10.6 %Revenue growth +8.8 %Cheap for the growth

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 12 %
2023
Rev +6%Profit +9%
2024
Rev +7%Profit +11%
2025
Rev +4%Profit −12%

🔎 Detailed analyses

🏛️ Which US Congress members hold Chemed Corp. (CHE)?

1 Congress member has disclosed CHE buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Lisa McClain
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on CHE

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Oppenheimer  75% +8.4% 12
RBC Capital  59% +0.8% 17
B of A Securities  50% +15.8% 2

📊 What $1,000 invested in Chemed Corp. would be worth › open the full page

In short — $1,000 invested in Chemed Corp. 10 years ago would be worth $3,319 today, i.e. +13%/yr on average. Best year: 2017 (+57%), worst: 2025 (-24%). Price performance, excluding dividends.

If I'd invested $1,000 in Chemed Corp.

InvestmentWorth todayGain
1 years ago$829-17%
3 years ago$922-8%
5 years ago$899-10%
→ See Chemed Corp.'s full return history + gain calculator

Return by year (Chemed Corp.)

YearReturn$1,000 invested at year start
2026 (YTD)+9%$1,090 (+9%)
2025-24%$829 (-17%)
2024-5%$786 (-21%)
→ See Chemed Corp.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Chemed Corp.

Loading news…

📋 All analyst calls on CHE

Oppenheimer 
Jul 31, 26
▲ Outperform · 🎯$590
Price at call : $540.57 — upside +9%
Today : $520.27 — upside +13%
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
in progress (365j)
matures : Jul 31, 27
RBC Capital 
Jul 30, 26
■ Sector Perform neutral · not a buy · 🎯$548
Price at call : $532.25 — gap to target +3%
Today : $520.27 — gap to target +5%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Jul 30, 27
■ Neutral neutral · not a buy · 🎯$510
Price at call : $490.46 — gap to target +4%
Today : $520.27 — gap to target -2%
🎯 on CHE : 50% (2 calls matureds) · 📊 on Health : 64.8% · +20.2% (105 calls)
in progress (365j)
matures : Jul 9, 27
RBC Capital 
Apr 27, 26
■ Sector Perform neutral · not a buy · 🎯$436
Price at call : $421.1 — gap to target +4%
Today : $520.27 — gap to target -16%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Apr 27, 27
RBC Capital 
Feb 27, 26
■ Sector Perform neutral · not a buy · 🎯$422
Price at call : $421.4 — gap to target +0%
Today : $520.27 — gap to target -19%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Feb 27, 27
Oppenheimer 
Feb 27, 26
▲ Outperform · 🎯$500
Price at call : $421.4 — upside +19%
Today : $520.27 — upside -4%
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
in progress (365j)
matures : Feb 27, 27
Jefferies 
Jan 22, 26
■ Hold neutral · not a buy · 🎯$475
Price at call : $444.74 — gap to target +7%
Today : $520.27 — gap to target -9%
🎯 on CHE : no call matured yet · 📊 on Health : 49.1% · +10.3% (112 calls)
in progress (365j)
matures : Jan 22, 27
RBC Capital 
Nov 10, 25
▲ Outperform · 🎯$572
Price at call : $445.53 — upside +28%
Today : $520.27 — upside +10%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Nov 10, 26
See the other 43 calls, newest to oldest
▲ Buy · 🎯$595
Price at call : $457.89 — upside +30%
Today : $520.27 — upside +14%
🎯 on CHE : 50% (2 calls matureds) · 📊 on Health : 64.8% · +20.2% (105 calls)
in progress (365j)
matures : Sep 10, 26
Jefferies 
Sep 2, 25
▲ Buy · 🎯$550
Price at call : $464 — upside +19%
Today : $520.27 — upside +6%
🎯 on CHE : no call matured yet · 📊 on Health : 49.1% · +10.3% (112 calls)
in progress (365j)
matures : Sep 2, 26
RBC Capital 
Jul 31, 25
▲ Outperform · 🎯$589
Price at call : $417.85 — upside +41%
Today : $520.27 — upside +13%
Expected +41% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+29.4%
stock +29% · XLV +24%
matured Jul 31, 26
Oppenheimer 
Jul 31, 25
▲ Outperform · 🎯$580
Price at call : $412.3 — upside +41%
Today : $520.27 — upside +11%
Expected +41% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+29.1%
stock +29% · XLV +25%
matured Jul 31, 26
Jefferies 
Jul 25, 25
■ Hold neutral · not a buy · 🎯$500
Price at call : $470.72 — gap to target +6%
Today : $520.27 — gap to target -4%
🎯 on CHE : no call matured yet · 📊 on Health : 49.1% · +10.3% (112 calls)
in progress (365j)
matures : Jul 25, 26
RBC Capital 
Jun 30, 25
▲ Outperform · 🎯$640
Price at call : $483.92 — upside +32%
Today : $520.27 — upside +23%
Expected +32% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-0.6%
stock -1% · XLV +17%
matured Jun 30, 26
▲ Buy · 🎯$650
Price at call : $486.93 — upside +33%
Today : $520.27 — upside +25%
Expected +33% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 50% (2 calls matureds) · 📊 on Health : 64.8% · +20.2% (105 calls)
-4.3%
stock -4% · XLV +18%
matured Jun 30, 26
RBC Capital 
Apr 28, 25
▲ Outperform · 🎯$674
Price at call : $574.96 — upside +17%
Today : $520.27 — upside +30%
Expected +17% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-26.3%
stock -26% · XLV +3%
matured Apr 28, 26
RBC Capital 
Mar 14, 25
▲ Outperform · 🎯$667
Price at call : $608.07 — upside +10%
Today : $520.27 — upside +28%
Expected +10% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-34.5%
stock -34% · XLV +3%
matured Mar 14, 26
RBC Capital 
Nov 5, 24
▲ Outperform · 🎯$633
Price at call : $549.99 — upside +15%
Today : $520.27 — upside +22%
Expected +15% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-21.7%
stock -22% · XLV -1%
matured Nov 5, 25
RBC Capital 
May 21, 24
▲ Outperform · 🎯$697
Price at call : $558.12 — upside +25%
Today : $520.27 — upside +34%
Expected +25% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+0.6%
stock +1% · XLV -11%
matured May 21, 25
RBC Capital 
Mar 4, 24
▲ Outperform · 🎯$712
Price at call : $636.72 — upside +12%
Today : $520.27 — upside +37%
Expected +12% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-6.5%
stock -7% · XLV +3%
matured Mar 4, 25
Oppenheimer 
Feb 29, 24
▲ Outperform · 🎯$650
Price at call : $613.81 — upside +6%
Today : $520.27 — upside +25%
Expected +6% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
-3.7%
stock -4% · XLV +2%
matured Feb 28, 25
Oppenheimer 
Jan 17, 24
▲ Outperform · 🎯$625
Price at call : $593.06 — upside +5%
Today : $520.27 — upside +20%
Expected +5% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
-6.5%
stock -6% · XLV +1%
matured Jan 16, 25
RBC Capital 
Oct 30, 23
▲ Outperform · 🎯$604
Price at call : $562.65 — upside +7%
Today : $520.27 — upside +16%
Expected +7% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-4.8%
stock -5% · XLV +19%
matured Oct 29, 24
RBC Capital 
Jul 31, 23
▲ Outperform · 🎯$576
Price at call : $520.99 — upside +11%
Today : $520.27 — upside +11%
Expected +11% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+9.4%
stock +9% · XLV +12%
matured Jul 30, 24
Oppenheimer 
Jul 27, 23
▲ Outperform · 🎯$590
Price at call : $523.21 — upside +13%
Today : $520.27 — upside +13%
Expected +13% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+6.0%
stock +6% · XLV +11%
matured Jul 26, 24
RBC Capital 
May 1, 23
▲ Outperform · 🎯$610
Price at call : $552.96 — upside +10%
Today : $520.27 — upside +17%
Expected +10% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+2.7%
stock +3% · XLV +5%
matured Apr 30, 24
Oppenheimer 
Apr 28, 23
▲ Outperform · 🎯$610
Price at call : $552.96 — upside +10%
Today : $520.27 — upside +17%
Expected +10% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+2.5%
stock +2% · XLV +5%
matured Apr 27, 24
RBC Capital 
Feb 27, 23
▲ Outperform · 🎯$587
Price at call : $535.55 — upside +10%
Today : $520.27 — upside +13%
Expected +10% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+11.4%
stock +11% · XLV +15%
matured Feb 27, 24
RBC Capital 
Nov 3, 22
▲ Outperform · 🎯$545
Price at call : $481.1 — upside +13%
Today : $520.27 — upside +5%
Expected +13% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+21.1%
stock +21% · XLV -2%
matured Nov 3, 23
RBC Capital 
Aug 1, 22
▲ Outperform · 🎯$541
Price at call : $470.28 — upside +15%
Today : $520.27 — upside +4%
Expected +15% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+10.8%
stock +11% · XLV +2%
matured Aug 1, 23
RBC Capital 
Apr 28, 22
▲ Outperform · 🎯$592
Price at call : $499.51 — upside +19%
Today : $520.27 — upside +14%
Expected +19% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+10.4%
stock +10% · XLV -0%
matured Apr 28, 23
RBC Capital 
Mar 4, 22
▲ Outperform · 🎯$579
Price at call : $485.9 — upside +19%
Today : $520.27 — upside +11%
Expected +19% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+6.2%
stock +6% · XLV -3%
matured Mar 4, 23
RBC Capital 
Jul 29, 21
▲ Outperform · 🎯$609
Price at call : $476.02 — upside +28%
Today : $520.27 — upside +17%
Expected +28% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
-1.2%
stock -1% · XLV -1%
matured Jul 29, 22
Oppenheimer 
Feb 25, 21
▲ Outperform · 🎯$580
Price at call : $445.21 — upside +30%
Today : $520.27 — upside +11%
Expected +30% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+7.4%
stock +7% · XLV +15%
matured Feb 25, 22
RBC Capital 
Mar 11, 20
▲ Outperform · 🎯$535
Price at call : $414.05 — upside +29%
Today : $520.27 — upside +3%
Expected +29% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
+7.0%
stock +7% · XLV +25%
matured Mar 11, 21
Oppenheimer 
Feb 19, 20
▲ Outperform · 🎯$535
Price at call : $487.26 — upside +10%
Today : $520.27 — upside +3%
Expected +10% · Actual -0% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
-0.2%
stock -0% · XLV +11%
matured Feb 18, 21
Oppenheimer 
Nov 25, 19
■ Perform neutral · not a buy · 🎯$470
Price at call : $427.75 — gap to target +10%
Today : $520.27 — gap to target -10%
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
in progress (365j)
matures : Nov 24, 20
▲ Market Outperform · 🎯$490
Price at call : $411.17 — upside +19%
Today : $520.27 — upside -6%
Expected +19% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 100% (1 call matured) · 📊 unranked overall
+17.1%
stock +17% · XLV +9%
matured Oct 31, 20
RBC Capital 
Feb 25, 19
■ Sector Perform neutral · not a buy · 🎯$318
Price at call : $326.45 — gap to target -3%
Today : $520.27 — gap to target -39%
🎯 on CHE : 59% (17 calls matureds) · 📊 on Health : 49.2% · +7.0% (195 calls)
in progress (365j)
matures : Feb 25, 20
▲ Buy · 🎯$390
Price at call : $303.24 — upside +29%
Today : $520.27 — upside -25%
Expected +29% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 50% (2 calls matureds) · 📊 on Health : 64.8% · +20.2% (105 calls)
+35.9%
stock +36% · XLV -1%
matured Oct 12, 19
Oppenheimer 
Oct 27, 17
▲ Outperform · 🎯$225
Price at call : $222.65 — upside +1%
Today : $520.27 — upside -57%
Expected +1% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+25.2%
stock +25% · XLV +8%
matured Oct 27, 18
Keybanc 
Aug 28, 17
■ Sector Weight neutral · not a buy
🎯 on CHE : no call matured yet · 📊 on Health : 32.6% · -10.5% (43 calls)
in progress (365j)
matures : Aug 28, 18
Oppenheimer 
Sep 22, 15
▲ Outperform · 🎯$150
Price at call : $138.13 — upside +9%
Today : $520.27 — upside -71%
Expected +9% · Actual +1% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+1.2%
stock +1% · XLV +5%
matured Sep 21, 16
Oppenheimer 
Apr 29, 15
▲ Outperform · 🎯$130
Price at call : $117.82 — upside +10%
Today : $520.27 — upside -75%
Expected +10% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+11.8%
stock +12% · XLV -3%
matured Apr 28, 16
Deutsche Bank 
May 1, 14
■ Hold neutral · not a buy · 🎯$75
Price at call : $83.95 — gap to target -11%
Today : $520.27 — gap to target -86%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : May 1, 15
Deutsche Bank 
Oct 30, 13
■ Hold neutral · not a buy · 🎯$64
Price at call : $66.82 — gap to target -4%
Today : $520.27 — gap to target -88%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : Oct 30, 14
Deutsche Bank 
Sep 10, 13
■ Hold neutral · not a buy · 🎯$63
Price at call : $66.04 — gap to target -5%
Today : $520.27 — gap to target -88%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : Sep 10, 14
CL King
Jul 19, 13
■ Neutral neutral · not a buy
🎯 on CHE : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jul 19, 14
Oppenheimer 
Jun 11, 13
▲ Outperform · 🎯$85
Price at call : $72 — upside +18%
Today : $520.27 — upside -84%
Expected +18% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+25.1%
stock +25% · XLV +25%
matured Jun 11, 14
Deutsche Bank 
Apr 19, 13
■ Hold neutral · not a buy · 🎯$80
Price at call : $78.7 — gap to target +2%
Today : $520.27 — gap to target -85%
🎯 on CHE : no call matured yet · 📊 on Health : 53.8% · +9.7% (80 calls)
in progress (365j)
matures : Apr 19, 14
Oppenheimer 
Oct 3, 12
▲ Outperform · 🎯$80
Price at call : $70.09 — upside +14%
Today : $520.27 — upside -85%
Expected +14% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on CHE : 75% (12 calls matureds) · 📊 on Health : 53.6% · +4.5% (69 calls)
+2.6%
stock +3% · XLV +24%
matured Oct 3, 13

Frequently asked questions

Should I buy Chemed Corp. stock?

This isn't buy advice. For Chemed Corp., the analyst consensus is "Hold", with an average price target of $548 (+5% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 75% of the time (12 calls tracked on Chemed Corp.). We show the numbers — you decide.

Is it too late to buy Chemed Corp.? How high can it go?

The most bullish analyst target on Chemed Corp. is $590 (+13% above today's price); the average is $548. That's the upside they see. Check how reliable those analysts have actually been on Chemed Corp. on our site before trusting it.

Is Chemed Corp. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 3 analysts have a real record on Chemed Corp., the best hitting 75% over 12 calls. Current consensus: "Hold". Make your call on data, not noise.

What has Chemed Corp.'s past performance been?

Historical returns and a "how much if I had invested" calculator: CHE performance & returns.

Does Chemed Corp. pay a dividend?

Yield, consistency and growth history of the dividend: CHE's dividend.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)